<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-64046" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cannabidiol (CBD)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Meissner</surname>
            <given-names>Hannah</given-names>
          </name>
          <aff>Creighton University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cascella</surname>
            <given-names>Marco</given-names>
          </name>
          <aff>Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Via Mariano Semmola 80100, Napoli. Italy</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hannah Meissner declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marco Cascella declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-64046.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">This&#x000a0;activity focuses on cannabidiol's (CBD) role in&#x000a0;managing&#x000a0;refractory epilepsy.&#x000a0;Participants&#x000a0;will explore indications, actions, and contraindications pertinent to CBD's efficacy in managing Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. This discussion also thoroughly reviews CBD's mechanism of action, adverse event profile, and ongoing research trials involving this drug. Additionally, understanding CBD's pharmacology&#x000a0;helps healthcare professionals&#x000a0;to tailor treatment plans to individual patient needs. Enhancing patient care and optimizing outcomes in epilepsy, neuropathic pain, and anxiety disorders&#x000a0;requires&#x000a0;emphasis on the critical role of the interprofessional healthcare team in overseeing CBD therapy.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the indications for cannabidiol.</p></list-item><list-item><p>Determine&#x000a0;the importance of monitoring patients receiving cannabidiol therapy.</p></list-item><list-item><p>Assess contraindications and other relevant factors before prescribing cannabidiol.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from cannabidiol therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=64046&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=64046">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-64046.s2" sec-type="Indications">
        <title>Indications</title>
        <p><italic toggle="yes">Cannabis sativa</italic>, or Indian hemp (subfamily <italic toggle="yes">Cannaboideae</italic> of family <italic toggle="yes">Moraceae</italic>), is an annual herbaceous plant native to central and western Asia. The plant is cultivated for its medicinal properties and&#x000a0;as a natural textile fiber.&#x000a0;<italic toggle="yes">Cannabis sativa</italic> contains over 400 chemical compounds; approximately 80 are biologically active. The most&#x000a0;relevant cannabis compounds are cannabinoids, which are formed by a terpene combined with resorcinol (or&#x000a0;a benzopyranic ring system, according to a different nomenclature). There are about&#x000a0;60 cannabinoids. The most important psychoactive compound is tetrahydrocannabinol (THC), particularly the isomer delta (&#x00394;9-THC). Other&#x000a0;relevant compounds&#x000a0;include cannabidiol (CBD), cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), and olivetol. In addition to cannabinoids, the plant contains terpenoids such as &#x003b2;-myrcene, &#x003b2;-caryophyllene, D-limonene, linalool, piperidine, and P-cymene, as well as flavonoids such as quercetin.</p>
        <p>CBD is nonintoxicating as it does not&#x000a0;demonstrate psychoactive activity. However, it exerts several beneficial pharmacological effects. The compound has analgesic and anti-inflammatory activities mediated by inhibiting cyclooxygenase and lipoxygenase. This anti-inflammatory action is several hundred times&#x000a0;more potent than acetylsalicylic acid. Furthermore, cannabidiol inhibits the synthesis of leukotriene TXB4 in polymorphonuclear cells.<xref ref-type="bibr" rid="article-64046.r1">[1]</xref>&#x000a0;Several investigations have&#x000a0;confirmed&#x000a0;CBD's anxiolytic, antiemetic, antipsychotic, and neuroprotective antioxidant properties.<xref ref-type="bibr" rid="article-64046.r2">[2]</xref><xref ref-type="bibr" rid="article-64046.r3">[3]</xref></p>
        <p>In a recent document, the FDA highlighted the potential beneficial effects of cannabis derivatives. To date, the agency has not approved a marketing application for cannabis,&#x000a0;but it has approved&#x000a0;4 synthetic cannabis-related drug products. A licensed healthcare provider must prescribe these approved drugs.</p>
        <p>In brief, the FDA-approved products are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Synthetic cannabis-related drug products
<list list-type="bullet"><list-item><p>Two products containing the active ingredient dronabinol (a synthetic &#x00394;9-THC) for the treatment of anorexia associated with weight loss in patients with AIDS.<xref ref-type="bibr" rid="article-64046.r4">[4]</xref></p></list-item><list-item><p>A product containing nabilone&#x000a0;that is prescribed&#x000a0;for the treatment of nausea and vomiting associated with anticancer&#x000a0;chemotherapy.<xref ref-type="bibr" rid="article-64046.r5">[5]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>The cannabis-derived compound&#x000a0;cannabidiol</p>
          </list-item>
        </list>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The FDA-approved pharmaceutical-grade cannabidiol for&#x000a0;patients 1 year or older&#x000a0;with refractory seizures as a result of the following conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Lennox-Gastaut syndrome</p>
          </list-item>
          <list-item>
            <p>Dravet syndrome</p>
          </list-item>
          <list-item>
            <p>Tuberous sclerosis complex&#x000a0;<xref ref-type="bibr" rid="article-64046.r6">[6]</xref><xref ref-type="bibr" rid="article-64046.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>Lennox-Gastaut syndrome is characterized by multiple types of seizures, with the most common being tonic seizures. On EEG, it has a characteristic slow wave (&#x0003c;3 Hz) with a spike or sharp wave. The exact pathophysiology is unknown. First-line treatment consists of various antiepileptic drugs, with CBD&#x000a0;as adjuvant therapy. Children with Lennox-Gastaut syndrome usually have learning and intellectual disabilities.<xref ref-type="bibr" rid="article-64046.r8">[8]</xref></p>
        <p>Dravet syndrome&#x000a0;is typically diagnosed in&#x000a0;1-year-old children with frequent febrile seizures.&#x000a0;As the disease progresses, other seizures may develop, including status epilepticus. An EEG will initially be normal before progressing to slowing and severe generalized polyspikes. Dravet syndrome appears to be caused by a nonsense mutation in the SCN1A gene, though there are cases without this mutation. Treatment was purely symptomatic, with benzodiazepines and antiepileptics prescribed to prevent the development of status epilepticus. Children with Dravet syndrome often have motor, intellectual, and psychological disabilities.<xref ref-type="bibr" rid="article-64046.r9">[9]</xref>&#x000a0;</p>
        <p>After conducting an&#x000a0;assessment&#x000a0;of&#x000a0;randomized controlled trials evaluating the efficacy of CBD&#x000a0;for managing Lennox&#x02013;Gastaut (LGS) and Dravet syndromes (DS), a pharmaceutical-grade CBD formulation&#x000a0;received&#x000a0;approval from the U.S. Food and Drug Administration (FDA) in 2018.<xref ref-type="bibr" rid="article-64046.r7">[7]</xref><xref ref-type="bibr" rid="article-64046.r10">[10]</xref><xref ref-type="bibr" rid="article-64046.r11">[11]</xref></p>
        <p>Management of&#x000a0;seizures in patients with tuberous sclerosis complex (TSC) is generally&#x000a0;similar&#x000a0;to the approach for other epileptic conditions. Regulatory agencies have approved a specific formulation of pharmaceutical-grade CBD to treat seizures associated with TSC.<xref ref-type="bibr" rid="article-64046.r12">[12]</xref></p>
        <p>
<bold>Off-Label and Investigational Uses</bold>
</p>
        <p>According to the guidelines established by the American Society of Clinical Oncology (ASCO), for patients undergoing cancer treatment with refractory nausea or vomiting despite adhering to antiemetic prophylaxis protocols, clinicians may consider adding dronabinol, nabilone, or a quality-controlled oral 1:1 tetrahydrocannabinol/cannabidiol extract. Cannabis or cannabinoids&#x000a0;are just one alternative for refractory nausea and vomiting in adult&#x000a0;patients with cancer despite optimal prophylaxis. In&#x000a0;these cases, the ASCO guidelines suggest considering the addition of olanzapine or introducing a different antiemetic, such as a neurokinin-1 (NK-1) receptor antagonist, benzodiazepine, or dopamine antagonist.<xref ref-type="bibr" rid="article-64046.r13">[13]</xref>&#x000a0;</p>
        <p>CBD is currently under investigation as a potential therapy for various psychiatric, neurodegenerative, and inflammatory diseases.<xref ref-type="bibr" rid="article-64046.r14">[14]</xref><xref ref-type="bibr" rid="article-64046.r15">[15]</xref>&#x000a0;Current clinical studies are investigating the use of CBD&#x000a0;for mood disorders such as anxiety, chronic pain control, anti-inflammatory diseases, and neurodegenerative diseases such as Alzheimer and Parkinson disease. However, none of these trials have resulted in FDA approval of CBD oil for the management of these conditions.<xref ref-type="bibr" rid="article-64046.r16">[16]</xref><xref ref-type="bibr" rid="article-64046.r17">[17]</xref></p>
        <p>One study was conducted to investigate the effectiveness of acute migraine treatments using a combination of 6% tetrahydrocannabinol (THC) and 11% cannabidiol (CBD) compared to placebo. The results revealed that the combination treatment was notably more effective than placebo at the 2-hour mark post-treatment. Furthermore, the benefits of this treatment were sustained, with continued efficacy&#x000a0;noted at the 24-hour and 48-hour intervals.<xref ref-type="bibr" rid="article-64046.r18">[18]</xref></p>
        <p>An open-label, single-center, phase I trial evaluated CBD for patients with biochemically recurrent prostate cancer after primary definitive local therapy. CBD was initiated at 600 mg orally once daily, with escalation to 800 mg daily. At 12 weeks, 16 out of 18 patients (88%) were found to have&#x000a0;stable biochemical disease, with&#x000a0;1 patient demonstrating partial biochemical response and another experiencing elevated PSA levels. Patient-reported outcomes did not significantly change, but trends indicated improved tolerability of CBD, particularly in emotional functioning. Daily CBD dosage of 800 mg appeared safe and well-tolerated, warranting further investigation.<xref ref-type="bibr" rid="article-64046.r19">[19]</xref>&#x000a0;One recent cohort study has indicated that CBD demonstrates an antiseizure effect similar to that of conventional antiseizure medications, showing a favorable safety profile across different epilepsy subtypes.<xref ref-type="bibr" rid="article-64046.r20">[20]</xref>&#x000a0;THC/CBD formulations are used at higher dosages to treat spasticity in amyotrophic lateral sclerosis (ALS). However, further prospective studies and direct comparisons with other anti-spasticity medications are required to understand the efficacy and safety profile more clearly.<xref ref-type="bibr" rid="article-64046.r21">[21]</xref></p>
      </sec>
      <sec id="article-64046.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The mechanism of action for cannabidiol, especially concerning its anticonvulsant effect, has not been fully elucidated. CBD is known to have a low affinity for cannabinoid receptors CB1 and CB2, where it can&#x000a0;act as&#x000a0;an&#x000a0;agonist or antagonist.&#x000a0;The anti-inflammatory effects of CBD may be explained by its inverse agonist activity at the CB2 receptor.<xref ref-type="bibr" rid="article-64046.r22">[22]</xref> Cannabidiol is a partial agonist of the serotonin 5-HT1A receptor and an allosteric modulator of opioid receptors, specifically&#x000a0;&#x003bc; and &#x003b4;. Researchers postulate that CBD could agonize PPAR-&#x003b3; and affect intracellular calcium release.<xref ref-type="bibr" rid="article-64046.r16">[16]</xref><xref ref-type="bibr" rid="article-64046.r23">[23]</xref>&#x000a0;</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Cannabidiol typically reaches peak plasma concentration (Tmax)&#x000a0;between 2.5 and 5 hours. Coadministration with a high-fat, high-calorie meal significantly increases maximum plasma concentration (Cmax) and area under the curve (AUC) compared to fasting. A low-fat, low-calorie meal also&#x000a0;increases&#x000a0;Cmax and AUC, though to a lesser extent.&#x000a0;Administration of&#x000a0;CBD with bovine milk or alcohol results in higher Cmax and AUC. Bioavailability through inhalation (smoking) is approximately 31%.</p>
        <p><bold>Distribution:</bold>&#x000a0;Cannabidiol's volume of distribution (Vd) ranges from 20,963 L to 42,849 L in healthy volunteers. CBD and its metabolites&#x000a0;are more than 94% protein-bound.</p>
        <p><bold>Metabolism:</bold> Cannabidiol&#x000a0;is metabolized primarily in the liver and intestines by CYP3A4 and CYP2C19 enzymes. CBD inhibits&#x000a0;UDP-glucuronosyltransferase (UGT) enzymes, including UGT1A9, UGT1A6, UGT2B7 and UGT2B4.<xref ref-type="bibr" rid="article-64046.r24">[24]</xref></p>
        <p><bold>Excretion:</bold>&#x000a0;Cannabidiol is primarily excreted in feces and minimally in urine. CBD's half-life after oromucosal administration (spray) is between&#x000a0;1.4 and 10.9&#x000a0;hours, 2 and 5 days after chronic oral consumption, and 31 hours after smoking.<xref ref-type="bibr" rid="article-64046.r25">[25]</xref></p>
      </sec>
      <sec id="article-64046.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strength</bold>
</p>
        <p>Cannabidiol is typically administered orally.<xref ref-type="bibr" rid="article-64046.r26">[26]</xref>&#x000a0;When needed, cannabidiol&#x000a0;may be administered through nasogastric or gastrostomy tubes.&#x000a0;Pharmaceutical CBD oil is available as an&#x000a0;oral solution&#x000a0;with a 100&#x000a0;mg/mL dosage.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>Lennox-Gastaut Syndrome or Dravet Syndrome:&#x000a0;</bold>Dosing with CBD should begin at lower&#x000a0;concentrations and titrate up to clinical levels.&#x000a0;In patients 12 months and older, the initial dose should be 2.5 mg/kg orally twice daily. The maintenance dose is 10 to 20 mg/kg/d. If the patient has tolerated CBD therapy for&#x000a0;a week, the dose may be increased to 5 mg/kg twice daily. The dose can be increased by 2.5 mg/kg twice daily, every other day, as tolerated.&#x000a0;For patients with Lennox-Gastaut Syndrome, the maximum dose is 20 mg/kg/d. For patients with Dravet syndrome, the maximum dose is 20 mg/kg/d. Patients who need a more rapid titration may gradually increase the dose daily.<xref ref-type="bibr" rid="article-64046.r27">[27]</xref><xref ref-type="bibr" rid="article-64046.r28">[28]</xref></p>
        <p>
<bold>Tuberous Sclerosis Complex</bold>
</p>
        <p>The initial suggested dose is 2.5 mg/kg orally twice daily (equivalent to 5 mg/kg/d). This dosage may be increased weekly by 2.5 mg/kg (equivalent to 5 mg/kg/d) as tolerated, up to a maintenance dose of 12.5 mg/kg orally twice daily (equivalent to 25 mg/kg/d).<xref ref-type="bibr" rid="article-64046.r29">[29]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;Dosages must be&#x000a0;titrated slowly&#x000a0;for patients with hepatic impairment, as&#x000a0;cannabidiol can cause liver damage.&#x000a0;CBD dosing remains unchanged in individuals with mild (Child-Pugh A) hepatic impairment.<xref ref-type="bibr" rid="article-64046.r27">[27]</xref>&#x000a0;According to FDA-approved product labeling, the recommended dosage for hepatic impairment is as follows:</p>
        <table-wrap id="article-64046.table0" position="float" orientation="portrait">
          <table style="width: 800px;" border="1" cellspacing="0" cellpadding="2">
            <tbody>
              <tr style="height: 62px;">
                <td style="width: 198.337px; height: 62px; text-align: center;" rowspan="1" colspan="1">
<bold>Hepatic Impairment</bold>
</td>
                <td style="width: 117.938px; height: 62px; text-align: center;" rowspan="1" colspan="1">
<bold>Starting Dosage</bold>
</td>
                <td style="width: 285.038px; height: 62px; text-align: center;" rowspan="1" colspan="1">
<p><bold>Lennox-Gastaut Syndrome or Dravet Syndrome</bold></p>
<p><bold>&#x000a0; &#x000a0; (Maintenance dose)</bold></p>
</td>
                <td style="width: 197.688px; height: 62px; text-align: center;" rowspan="1" colspan="1">
<p><bold>Tuberous Sclerosis Complex</bold></p>
<p><bold>(Maintenance dose)</bold></p>
</td>
              </tr>
              <tr style="height: 27.125px;">
                <td style="width: 198.337px; height: 27.125px; text-align: center;" rowspan="1" colspan="1">
<bold>Mild hepatic impairment</bold>
</td>
                <td style="width: 117.938px; height: 27.125px; text-align: center;" rowspan="1" colspan="1">5 mg/kg/d</td>
                <td style="width: 285.038px; height: 27.125px; text-align: center;" rowspan="1" colspan="1">
<p>10 to 20 mg/kg/d</p>
</td>
                <td style="width: 197.688px; height: 27.125px; text-align: center;" rowspan="1" colspan="1">
<p>25 mg/kg/d</p>
</td>
              </tr>
              <tr style="height: 46px;">
                <td style="width: 198.337px; height: 46px; text-align: center;" rowspan="1" colspan="1">
<bold>Moderate hepatic impairment</bold>
</td>
                <td style="width: 117.938px; height: 46px; text-align: center;" rowspan="1" colspan="1">2.5 mg/kg/d</td>
                <td style="width: 285.038px; height: 46px; text-align: center;" rowspan="1" colspan="1">5 to 10 mg/kg/d</td>
                <td style="width: 197.688px; height: 46px; text-align: center;" rowspan="1" colspan="1">12.5 mg/kg/d</td>
              </tr>
              <tr style="height: 46px;">
                <td style="width: 198.337px; height: 46px; text-align: center;" rowspan="1" colspan="1">
<bold>Severe hepatic impairment</bold>
</td>
                <td style="width: 117.938px; height: 46px; text-align: center;" rowspan="1" colspan="1">1 mg/kg/d</td>
                <td style="width: 285.038px; height: 46px; text-align: center;" rowspan="1" colspan="1">2 to 4 mg/kg/d</td>
                <td style="width: 197.688px; height: 46px; text-align: center;" rowspan="1" colspan="1">5 mg/kg/d</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p><bold>Renal impairment:</bold> The product labeling does not provide dosage adjustments for cannabidiol&#x000a0;due to impaired kidney function.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>The American College of Obstetricians and Gynecologists (ACOG) advises healthcare providers to inquire about substance use, including marijuana, before and during pregnancy. Pregnant women should be counseled on the potential risks associated with marijuana use and encouraged to stop using it.<xref ref-type="bibr" rid="article-64046.r30">[30]</xref>&#x000a0;Pregnant women using cannabidiol should be encouraged to participate in pregnancy registries. There is insufficient data&#x000a0;concerning the effect of&#x000a0;cannabidiol on fetal development during pregnancy. Preclinical investigations have demonstrated that high doses of fetal CBD exposure may&#x000a0;alter&#x000a0;thermal pain sensitivity, problem-solving behaviors, and the excitability of pyramidal neurons in the prefrontal cortex. CBD intake during pregnancy may&#x000a0;have detrimental long-term neurodevelopmental consequences.<xref ref-type="bibr" rid="article-64046.r31">[31]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Cannabidiol has not been&#x000a0;investigated in women who are breastfeeding. Due to the lack of published data on cannabidiol as an antiepileptic during breastfeeding, an alternative medication is advised, particularly when preterm infants are being nursed.<xref ref-type="bibr" rid="article-64046.r32">[32]</xref></p>
        <p><bold>Pediatric patients: </bold>The FDA has approved cannabidiol for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in all age groups.</p>
        <p><bold>Older patients:&#x000a0;</bold>Clinicians should initiate CBD&#x000a0;therapy&#x000a0;at lower&#x000a0;doses&#x000a0;for older&#x000a0;adults due to potential reductions in renal and hepatic function and concurrent drug therapy.</p>
      </sec>
      <sec id="article-64046.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Liver Damage</bold>
</p>
        <p>CBD can cause dose-dependent&#x000a0;hepatotoxicity. Concomitant use of CBD and other medications, including leflunomide, lomitapide, mipomersen, pexidartinib, teriflunomide, and valproate, is known to cause liver damage. Clinicians should warn patients with elevated baseline transaminase levels about the risk of exacerbating liver function&#x000a0;while taking CBD. Providers should monitor bilirubin and transaminase levels before and during treatment.&#x000a0;According to ASCO guidelines, hepatotoxicity is&#x000a0;primarily observed&#x000a0;when&#x000a0;CBD is administered orally at daily doses of 300 mg or greater.<xref ref-type="bibr" rid="article-64046.r13">[13]</xref> Discontinuation of CBD or discontinuing concomitant use reduces these elevations. In patients with moderate or severe liver damage, slow titration and dosage adjustment&#x000a0;are&#x000a0;recommended.<xref ref-type="bibr" rid="article-64046.r33">[33]</xref><xref ref-type="bibr" rid="article-64046.r34">[34]</xref>&#x000a0;</p>
        <p>
<bold>Other Adverse Effects</bold>
</p>
        <p>Reports of malaise, asthenia, and sedation associated with CBD use have been documented. These&#x000a0;adverse&#x000a0;effects may diminish over time and are more likely to be reported earlier in treatment. A meta-analysis demonstrated that CBD treatment is linked to somnolence, diarrhea, and transaminitis.<xref ref-type="bibr" rid="article-64046.r35">[35]</xref></p>
        <p>Cannabidiol&#x000a0;may&#x000a0;be associated with&#x000a0;increased suicidal thoughts and behaviors.<xref ref-type="bibr" rid="article-64046.r36">[36]</xref>&#x000a0;When prescribing CBD, the physician should warn patients and caregivers to watch for any unusual changes in mood or behaviors. Any changes require evaluating whether they result from&#x000a0;CBD, other medications, or underlying illnesses.</p>
        <p>CBD is only recently available and is usually used as an adjunct therapy; further&#x000a0;investigations&#x000a0;are necessary to better&#x000a0;comprehend potential&#x000a0;adverse&#x000a0;effects and effects on liver enzymes and drug interactions.<xref ref-type="bibr" rid="article-64046.r37">[37]</xref><xref ref-type="bibr" rid="article-64046.r1">[1]</xref>&#x000a0;Post-marketing surveillance has revealed cortical visual impairment and a hyperactive pharyngeal reflex as potential adverse effects of CBD.<xref ref-type="bibr" rid="article-64046.r38">[38]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The coadministration of rifampin, a strong CYP3A4 inducer, decreases plasma concentrations of cannabidiol.<xref ref-type="bibr" rid="article-64046.r39">[39]</xref></p>
          </list-item>
          <list-item>
            <p>Cannabidiol weakly inhibits CYP1A2, potentially increasing exposure to caffeine, theophylline, or tizanidine.</p>
          </list-item>
          <list-item>
            <p>In vitro data suggest potential drug-drug interactions with CYP2B6 substrates, including bupropion and efavirenz, UGT1A9 substrates (eg, propofol and fenofibrate), and UGT2B7 substrates (eg, gemfibrozil, lamotrigine, morphine, and lorazepam) when coadministered with cannabidiol. Cannabidiol may also interact with CYP2C8 and CYP2C9 substrates such as phenytoin. Dosage adjustments of these substrates may be necessary if adverse reactions occur&#x000a0;during coadministration.</p>
          </list-item>
          <list-item>
            <p>Coadministration of cannabidiol may increase plasma concentrations of drugs metabolized by CYP2C19 (eg, diazepam), potentially raising the risk of adverse reactions. Reducing the dosage of sensitive CYP2C19 substrates may be&#x000a0;necessary when coadministered with cannabidiol.</p>
          </list-item>
          <list-item>
            <p>Cannabidiol coadministration increases plasma concentrations of N-desmethyl clobazam, the active metabolite of clobazam. If adverse reactions occur with cannabidiol coadministration, clobazam dose reduction should be considered.</p>
          </list-item>
          <list-item>
            <p>Concomitant use of cannabidiol and stiripentol may&#x000a0;increase exposure to stiripentol, though the mechanism of this interaction is unclear. Patients should be monitored for stiripentol-related adverse drug reactions.<xref ref-type="bibr" rid="article-64046.r40">[40]</xref></p>
          </list-item>
          <list-item>
            <p>Coadministration of cannabidiol with everolimus, a P-glycoprotein and CYP3A4 substrate, increases everolimus exposure.&#x000a0; Monitoring of everolimus levels and adverse effects is recommended when initiating cannabidiol therapy in patients taking this medication.</p>
          </list-item>
          <list-item>
            <p>The concurrent use of cannabidiol&#x000a0;with drugs like&#x000a0;valproate&#x000a0;increases the&#x000a0;risk of hepatotoxicity.<xref ref-type="bibr" rid="article-64046.r41">[41]</xref>&#x000a0;Liver function tests&#x000a0;should be performed regularly, and discontinuation or reduction of cannabidiol should be considered if there is significant hepatotoxicity.</p>
          </list-item>
          <list-item>
            <p>Clinicians&#x000a0;should be cautious about prescribing CBD with other sedative medications, such as benzodiazepines and opioids. Concomitant use of CBD with these sedative medications can result in severe respiratory depression.<xref ref-type="bibr" rid="article-64046.r42">[42]</xref><xref ref-type="bibr" rid="article-64046.r43">[43]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-64046.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Absolute contraindications to CBD&#x000a0;include an allergy to cannabidiol or sesame oil. At the first signs of cutaneous irritation or anaphylactic reaction, the patient should stop using CBD.<xref ref-type="bibr" rid="article-64046.r44">[44]</xref><xref ref-type="bibr" rid="article-64046.r45">[45]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p><bold>Substance use disorder:</bold> In patients with a history of substance use disorder, providers should be cautious when prescribing CBD. While CBD does not contain the part of marijuana that gives users a &#x0201c;high,&#x0201d; it may be addictive. Physicians should caution patients who have struggled with addiction about this and emphasize appropriate use. In these cases, clinicians should&#x000a0;determine&#x000a0;the risk vs. benefit ratio.</p>
        <p><bold>Suicidal ideations:</bold>&#x000a0;Cannabidiol should be used with caution for patients with a history of mood disorders, depression, or suicidal thoughts; patients with a history of these should be cautioned about using CBD, as is&#x000a0;correlated with increased suicidal thoughts and behavior. Physicians should&#x000a0;determine the risk vs. benefit ratio and&#x000a0;advise patients and their caregivers to watch for sudden changes in behavior.<xref ref-type="bibr" rid="article-64046.r46">[46]</xref><xref ref-type="bibr" rid="article-64046.r36">[36]</xref></p>
        <p><bold>Hepatotoxicity:</bold> Cholestatic&#x000a0;and mixed patterns of&#x000a0;drug-induced liver injury (based on the&#x000a0;alanine aminotransferase (ALT) to the upper limit of normal (ULN) and alkaline phosphatase (ALP) to ULN&#x000a0;ratios) have been reported in patients treated with cannabidiol.</p>
        <p><bold>Rapid discontinuation:</bold>&#x000a0;Although improved seizure control has been observed&#x000a0;on a dosage of 20 mg/kg/d, this is accompanied by a higher incidence of adverse reactions. CBD use should not be discontinued abruptly. Sudden discontinuation can cause an increase in seizure frequency and possibly status epilepticus.<xref ref-type="bibr" rid="article-64046.r27">[27]</xref></p>
      </sec>
      <sec id="article-64046.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Due to the potential negative effects of CBD on the liver, transaminase and bilirubin levels must be measured before and after&#x000a0;treatment initiation. If&#x000a0;these levels increase before treatment, this may be a sign of underlying liver damage. By measuring transaminase levels during treatment, earlier identification of potential liver damage may be identified, and CBD dosing may be titrated down. These levels should be obtained 1 month before and 3 months after initiating treatment. After&#x000a0;any change in dose&#x000a0;or addition of a medication known to affect the liver, transaminase and bilirubin levels should be obtained&#x000a0;monthly&#x000a0;from patients who have liver damage or take drugs known to cause hepatotoxicity (eg, valproate, clobazam).</p>
        <p>Transaminase and total bilirubin levels should be obtained immediately at the first signs of liver dysfunction, such as right upper quadrant pain, nausea, vomiting, jaundice, and dark urine. If transaminase levels are greater than&#x000a0;5 times the upper limit of normal or greater than&#x000a0;3 times the upper limit, and bilirubin levels are greater than&#x000a0;2 times the upper limit of normal, treatment should be discontinued.<xref ref-type="bibr" rid="article-64046.r47">[47]</xref><xref ref-type="bibr" rid="article-64046.r48">[48]</xref>&#x000a0;</p>
        <p>According to ASCO guidelines, hepatotoxicity is predominantly observed in adult and pediatric populations administered oral CBD at daily doses of 300 mg or&#x000a0;greater. Federal legislation has sanctioned cannabis with increased&#x000a0;CBD levels and minimal THC content.<xref ref-type="bibr" rid="article-64046.r13">[13]</xref>&#x000a0;The American Society of Regional Anesthesia and Pain Medicine (ASRA) recommends delaying elective surgery for a minimum of 2 hours after cannabis smoking due to the increased perioperative risk of acute myocardial infarction.<xref ref-type="bibr" rid="article-64046.r49">[49]</xref></p>
      </sec>
      <sec id="article-64046.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Reports of required ventilation support for children and older&#x000a0;adults&#x000a0;after ingesting&#x000a0;excessive&#x000a0;cannabis amounts have been documented.<xref ref-type="bibr" rid="article-64046.r50">[50]</xref>&#x000a0;CBD is associated with worsening respiratory depression in patients taking other respiratory-depressing drugs, such as opioids and benzodiazepines. In these scenarios, respiratory support is the mainstay of treatment; there is no antidote to CBD or cannabis toxicity.<xref ref-type="bibr" rid="article-64046.r11">[11]</xref><xref ref-type="bibr" rid="article-64046.r51">[51]</xref><xref ref-type="bibr" rid="article-64046.r47">[47]</xref><xref ref-type="bibr" rid="article-64046.r50">[50]</xref></p>
      </sec>
      <sec id="article-64046.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>FDA&#x000a0;approval of CBD for the treatment of Lennox-Gastaut syndrome, Dravet syndrome, and Tuberous sclerosis complex has&#x000a0;significantly improved&#x000a0;the lives of patients and their families. Pediatric neurologists should be consulted for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Due to CBD's&#x000a0;adverse effects (particularly on the liver),&#x000a0;regular&#x000a0;liver function monitoring is recommended.&#x000a0;Pharmacists should perform medication reconciliation, report any significant drug interactions, and educate&#x000a0;caregivers on potential adverse effects. Nurses are vital in educating patients about proper dosing, monitoring, and providing support throughout treatment.&#x000a0;CBD's therapeutic potential may be far more widespread than initially believed;&#x000a0;researchers and clinicians&#x000a0;should continue to evaluate and identify&#x000a0;CBD's uses. Due to differing state laws&#x000a0;regarding&#x000a0;marijuana, social workers and other relevant healthcare professionals must help caregivers&#x000a0;and patients understand that CBD is legal and is not the part of cannabis that makes its users high. Proper&#x000a0;administration of CBD has demonstrated a reduction in seizure frequency in these syndromes, which are notoriously difficult to treat. An interprofessional team approach and open communication between clinicians (MDs, DOs, NPs, PAs), pharmacists, neurologists, and nurses are necessary to&#x000a0;optimize outcomes for&#x000a0;patients on cannabidiol therapy.</p>
        <p>CBD reduces seizures and increases seizure control. In particular,</p>
        <list list-type="bullet">
          <list-item>
            <p>CBD, used as an adjunct therapy in Lennox-Gastaut syndrome or Dravet syndrome without seizure control by anti-epileptics, significantly reduces seizure frequency.<xref ref-type="bibr" rid="article-64046.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>CBD is known to cause hepatotoxicity;&#x000a0;periodic liver&#x000a0;function testing (LFTs) is necessary.<xref ref-type="bibr" rid="article-64046.r47">[47]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-64046.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=64046&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=64046">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/64046/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=64046">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-64046.s11">
        <title>References</title>
        <ref id="article-64046.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iffland</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Grotenhermen</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.</article-title>
            <source>Cannabis Cannabinoid Res</source>
            <year>2017</year>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>139</fpage>
            <page-range>139-154</page-range>
            <pub-id pub-id-type="pmid">28861514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davies</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bhattacharyya</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cannabidiol as a potential treatment for psychosis.</article-title>
            <source>Ther Adv Psychopharmacol</source>
            <year>2019</year>
            <volume>9</volume>
            <fpage>2045125319881916</fpage>
            <pub-id pub-id-type="pmid">31741731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ju</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease.</article-title>
            <source>Eur J Med Chem</source>
            <year>2020</year>
            <month>Apr</month>
            <day>15</day>
            <volume>192</volume>
            <fpage>112163</fpage>
            <pub-id pub-id-type="pmid">32109623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>O'Donnell</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Meissner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <chapter-title>Dronabinol</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">32491463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bathula</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Maciver</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Cannabinoids in Treating Chemotherapy-Induced Nausea and Vomiting, Cancer-Associated Pain, and Tumor Growth.</article-title>
            <source>Int J Mol Sci</source>
            <year>2023</year>
            <month>Dec</month>
            <day>20</day>
            <volume>25</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">38203245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thiele</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Bebin</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Filloux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Loftus</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sahebkar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sparagana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wheless</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial.</article-title>
            <source>Epilepsia</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>426</fpage>
            <page-range>426-439</page-range>
            <pub-id pub-id-type="pmid">34957550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samanta</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development.</article-title>
            <source>Epilepsy Behav</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>128</volume>
            <fpage>108577</fpage>
            <pub-id pub-id-type="pmid">35151190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asadi-Pooya</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Lennox-Gastaut syndrome: a comprehensive review.</article-title>
            <source>Neurol Sci</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>403</fpage>
            <page-range>403-414</page-range>
            <pub-id pub-id-type="pmid">29124439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wirrell</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Dravet Syndrome.</article-title>
            <source>Can J Neurol Sci</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>43 Suppl 3</volume>
            <fpage>S13</fpage>
            <page-range>S13-8</page-range>
            <pub-id pub-id-type="pmid">27264138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lattanzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brigo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Trinka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zaccara</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Striano</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Del Giovane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Silvestrini</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety.</article-title>
            <source>CNS Drugs</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>229</fpage>
            <page-range>229-241</page-range>
            <pub-id pub-id-type="pmid">32040850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silvestro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mammana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bramanti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mazzon</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.</article-title>
            <source>Molecules</source>
            <year>2019</year>
            <month>Apr</month>
            <day>12</day>
            <volume>24</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">31013866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stuart</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fladrowski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Flinn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>&#x000d6;berg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Peron</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rozenberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Beyond the Guidelines: How We Can Improve Healthcare for People With Tuberous Sclerosis Complex Around the World.</article-title>
            <source>Pediatr Neurol</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>123</volume>
            <fpage>77</fpage>
            <page-range>77-84</page-range>
            <pub-id pub-id-type="pmid">34416612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braun</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Bohlke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Balneaves</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Bar-Sela</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bowles</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Chai</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Damani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hallmeyer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Subbiah</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Twelves</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Roeland</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline.</article-title>
            <source>J Clin Oncol</source>
            <year>2024</year>
            <month>May</month>
            <day>01</day>
            <volume>42</volume>
            <issue>13</issue>
            <fpage>1575</fpage>
            <page-range>1575-1593</page-range>
            <pub-id pub-id-type="pmid">38478773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laczkovics</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kothgassner</surname>
                <given-names>OD</given-names>
              </name>
              <name>
                <surname>Felnhofer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Klier</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression.</article-title>
            <source>Neuropsychiatr</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-34</page-range>
            <pub-id pub-id-type="pmid">32052321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levinsohn</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>KP</given-names>
              </name>
            </person-group>
            <article-title>Clinical uses of cannabis and cannabinoids in the United States.</article-title>
            <source>J Neurol Sci</source>
            <year>2020</year>
            <month>Apr</month>
            <day>15</day>
            <volume>411</volume>
            <fpage>116717</fpage>
            <pub-id pub-id-type="pmid">32044684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crippa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Guimar&#x000e3;es</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Campos</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Zuardi</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.</article-title>
            <source>Front Immunol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>2009</fpage>
            <pub-id pub-id-type="pmid">30298064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Karl</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title><italic>In vivo</italic> Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease.</article-title>
            <source>Front Pharmacol</source>
            <year>2017</year>
            <volume>8</volume>
            <fpage>20</fpage>
            <pub-id pub-id-type="pmid">28217094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schuster</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Marcotte</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sexton</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Vaporized Cannabis versus Placebo for Acute Migraine: A Randomized Controlled Trial.</article-title>
            <source>medRxiv</source>
            <year>2024</year>
            <month>Feb</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">38405890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Myint</surname>
                <given-names>ZW</given-names>
              </name>
              <name>
                <surname>St Clair</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Strup</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Allison</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>McLouth</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hensley</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>DiPaola</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Kolesar</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer.</article-title>
            <source>Cancers (Basel)</source>
            <year>2023</year>
            <month>Apr</month>
            <day>27</day>
            <volume>15</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">37173971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000fc;hne</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Bast</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bertsche</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Borggraefe</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bo&#x000df;elmann</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Fahrbach</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hertzberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Herz</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Holtkamp</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Janello</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Kurlemann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lerche</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Makridis</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>von Podewils</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pringsheim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schubert-Bast</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schulz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schulze-Bonhage</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Steinbart</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Steinhoff</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Strzelczyk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Syrbe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Vries</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilken</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Prager</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Klotz</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Kaindl</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study.</article-title>
            <source>Epilepsia Open</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>360</fpage>
            <page-range>360-370</page-range>
            <pub-id pub-id-type="pmid">36693811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Funke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>M&#x000fc;nch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kettemann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Spittel</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD).</article-title>
            <source>BMC Neurol</source>
            <year>2019</year>
            <month>Sep</month>
            <day>07</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>222</fpage>
            <pub-id pub-id-type="pmid">31493784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schwenk</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Narouze</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids: an infographic.</article-title>
            <source>Reg Anesth Pain Med</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>119</fpage>
            <pub-id pub-id-type="pmid">36596581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gray</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Whalley</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>The proposed mechanisms of action of CBD in epilepsy.</article-title>
            <source>Epileptic Disord</source>
            <year>2020</year>
            <month>Jan</month>
            <day>01</day>
            <volume>22</volume>
            <issue>S1</issue>
            <fpage>10</fpage>
            <page-range>10-15</page-range>
            <pub-id pub-id-type="pmid">32053110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasrin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>CJW</given-names>
              </name>
              <name>
                <surname>Bardhi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fort</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lazarus</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of UDP-Glucuronosyltransferase Enzymes by Major Cannabinoids and Their Metabolites.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>49</volume>
            <issue>12</issue>
            <fpage>1081</fpage>
            <page-range>1081-1089</page-range>
            <pub-id pub-id-type="pmid">34493601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Millar</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Yates</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>O'Sullivan</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans.</article-title>
            <source>Front Pharmacol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>1365</fpage>
            <pub-id pub-id-type="pmid">30534073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacCallum</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>Practical considerations in medical cannabis administration and dosing.</article-title>
            <source>Eur J Intern Med</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>49</volume>
            <fpage>12</fpage>
            <page-range>12-19</page-range>
            <pub-id pub-id-type="pmid">29307505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Connell</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Devinsky</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Cannabinoids in treatment-resistant epilepsy: A review.</article-title>
            <source>Epilepsy Behav</source>
            <year>2017</year>
            <month>May</month>
            <volume>70</volume>
            <issue>Pt B</issue>
            <fpage>341</fpage>
            <page-range>341-348</page-range>
            <pub-id pub-id-type="pmid">28188044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devinsky</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Appleton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Harden</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Greenwood</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sommerville</surname>
                <given-names>K</given-names>
              </name>
              <collab>GWPCARE1 Part A Study Group</collab>
            </person-group>
            <article-title>Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.</article-title>
            <source>Neurology</source>
            <year>2018</year>
            <month>Apr</month>
            <day>03</day>
            <volume>90</volume>
            <issue>14</issue>
            <fpage>e1204</fpage>
            <page-range>e1204-e1211</page-range>
            <pub-id pub-id-type="pmid">29540584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mora Rodriguez</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cobb</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Leatheng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kutluay</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Quality improvement study in epilepsy patients treated with Epidiolex&#x000ae;.</article-title>
            <source>J Neurol Sci</source>
            <year>2023</year>
            <month>Aug</month>
            <day>15</day>
            <volume>451</volume>
            <fpage>120712</fpage>
            <pub-id pub-id-type="pmid">37390612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <article-title>Committee Opinion No. 722: Marijuana Use During Pregnancy and Lactation.</article-title>
            <source>Obstet Gynecol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>130</volume>
            <issue>4</issue>
            <fpage>e205</fpage>
            <page-range>e205-e209</page-range>
            <pub-id pub-id-type="pmid">28937574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swenson</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Gomez Wulschner</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Hoelscher</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Folts</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Korth</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Fetal cannabidiol (CBD) exposure alters thermal pain sensitivity, problem-solving, and prefrontal cortex excitability.</article-title>
            <source>Mol Psychiatry</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>8</issue>
            <fpage>3397</fpage>
            <page-range>3397-3413</page-range>
            <pub-id pub-id-type="pmid">37433966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r32">
          <label>32</label>
          <element-citation publication-type="book">
            <chapter-title>Cannabidiol</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>10</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30601607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Borgelt</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Blackmer</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.</article-title>
            <source>Ann Pharmacother</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>53</volume>
            <issue>6</issue>
            <fpage>603</fpage>
            <page-range>603-611</page-range>
            <pub-id pub-id-type="pmid">30616356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Winterstein</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use.</article-title>
            <source>J Clin Med</source>
            <year>2019</year>
            <month>Jul</month>
            <day>08</day>
            <volume>8</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">31288397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fazlollahi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zahmatyar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>ZareDini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Golabi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nejadghaderi</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Sullman</surname>
                <given-names>MJM</given-names>
              </name>
              <name>
                <surname>Gharagozli</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kolahi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Safiri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Adverse Events of Cannabidiol Use in Patients With Epilepsy: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA Netw Open</source>
            <year>2023</year>
            <month>Apr</month>
            <day>03</day>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>e239126</fpage>
            <pub-id pub-id-type="pmid">37079302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>59</volume>
            <issue>7</issue>
            <fpage>923</fpage>
            <page-range>923-934</page-range>
            <pub-id pub-id-type="pmid">30730563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergamaschi</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Queiroz</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Zuardi</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Crippa</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Safety and side effects of cannabidiol, a Cannabis sativa constituent.</article-title>
            <source>Curr Drug Saf</source>
            <year>2011</year>
            <month>Sep</month>
            <day>01</day>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>237</fpage>
            <page-range>237-49</page-range>
            <pub-id pub-id-type="pmid">22129319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Adverse events of epidiolex: A real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database.</article-title>
            <source>Asian J Psychiatr</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>90</volume>
            <fpage>103828</fpage>
            <pub-id pub-id-type="pmid">37949044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balachandran</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Elsohly</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>KP</given-names>
              </name>
            </person-group>
            <article-title>Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review.</article-title>
            <source>J Gen Intern Med</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>36</volume>
            <issue>7</issue>
            <fpage>2074</fpage>
            <page-range>2074-2084</page-range>
            <pub-id pub-id-type="pmid">33515191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morrison</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Crockett</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blakey</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sommerville</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects.</article-title>
            <source>Clin Pharmacol Drug Dev</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>8</volume>
            <issue>8</issue>
            <fpage>1009</fpage>
            <page-range>1009-1031</page-range>
            <pub-id pub-id-type="pmid">30791225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r41">
          <label>41</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Patel</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Nagalli</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Valproate Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">32809733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scheffer</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Sadleir</surname>
                <given-names>LG</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of cannabinoids in paediatric epilepsy.</article-title>
            <source>Dev Med Child Neurol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>61</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-18</page-range>
            <pub-id pub-id-type="pmid">30402932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaston</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Szaflarski</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Cannabis for the Treatment of Epilepsy: an Update.</article-title>
            <source>Curr Neurol Neurosci Rep</source>
            <year>2018</year>
            <month>Sep</month>
            <day>08</day>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>73</fpage>
            <pub-id pub-id-type="pmid">30194563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Antimisiaris</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Epidiolex-induced skin rash.</article-title>
            <source>Epileptic Disord</source>
            <year>2020</year>
            <month>Aug</month>
            <day>01</day>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>511</fpage>
            <page-range>511-514</page-range>
            <pub-id pub-id-type="pmid">32729550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abu-Sawwa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stehling</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Epidiolex (Cannabidiol) Primer: Frequently Asked Questions for Patients and Caregivers.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2020</year>
            <season>Jan-Feb</season>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-77</page-range>
            <pub-id pub-id-type="pmid">31897080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Serafini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pompili</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Innamorati</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rihmer</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sher</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Girardi</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Can cannabis increase the suicide risk in psychosis? A critical review.</article-title>
            <source>Curr Pharm Des</source>
            <year>2012</year>
            <volume>18</volume>
            <issue>32</issue>
            <fpage>5165</fpage>
            <page-range>5165-87</page-range>
            <pub-id pub-id-type="pmid">22716157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>VanDolah</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Mauck</surname>
                <given-names>KF</given-names>
              </name>
            </person-group>
            <article-title>Clinicians' Guide to Cannabidiol and Hemp&#x000a0;Oils.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>94</volume>
            <issue>9</issue>
            <fpage>1840</fpage>
            <page-range>1840-1851</page-range>
            <pub-id pub-id-type="pmid">31447137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaheer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Giyanwani</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Kiran</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Epilepsy and Cannabis: A Literature Review.</article-title>
            <source>Cureus</source>
            <year>2018</year>
            <month>Sep</month>
            <day>10</day>
            <volume>10</volume>
            <issue>9</issue>
            <fpage>e3278</fpage>
            <pub-id pub-id-type="pmid">30443449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schwenk</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Sondekoppam</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zakowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rzasa-Lynn</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Yeung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nicholson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hooten</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Viscusi</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Narouze</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids.</article-title>
            <source>Reg Anesth Pain Med</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>97</fpage>
            <page-range>97-117</page-range>
            <pub-id pub-id-type="pmid">36596580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Srisuma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bronstein</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hoyte</surname>
                <given-names>CO</given-names>
              </name>
            </person-group>
            <article-title>Characterization of edible marijuana product exposures reported to United States poison centers.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>54</volume>
            <issue>9</issue>
            <fpage>840</fpage>
            <page-range>840-846</page-range>
            <pub-id pub-id-type="pmid">27418198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-64046.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szkudlarek</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Renard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Norris</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jobson</surname>
                <given-names>CEL</given-names>
              </name>
              <name>
                <surname>Rajakumar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Allman</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Laviolette</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>&#x00394;-9-Tetrahydrocannabinol and Cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors.</article-title>
            <source>Neuropsychopharmacology</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>817</fpage>
            <page-range>817-825</page-range>
            <pub-id pub-id-type="pmid">30538288</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
